NLRP3 and atherosclerosis: Systemic inflammation, driven by metabolic diseases and risk factors such as obesity, chronic kidney disease, rheumatoid arthritis, and smoking, accelerates plaque progression and increases clinical event rates in ASCVD.7–9 A key player in this inflammatory process is the NLRP3 inflammasome, an intracellular protein complex within the inmate immune system.